Non-Compliance at Italian Sterile Manufacturer
Recommendation

16-18 June 2026
Good Engineering Practice for Pharmaceutical Companies and Suppliers
In the course of an inspection conducted in October 2018, the Italian health authority discovered several GMP deviations at an Italian manufacturer. The Italian manufacturer produces aseptically prepared LVPs (Large Volume Parenterals) and powders, as well as terminally sterilised LVPs. During the inspection, deficiencies were found in the areas of sterile products (both aseptically prepared and terminally sterilised), secondary packaging and quality control (microbiological, chemical/physical and biological.
The authority has reported 17 major and one "other" deficiencies. The major deficiencies concerned the qualification of critical equipment (autoclaves, depyrogenation tunnels, lyophilisers, CCI testing equipment for ampoules, visual inspection systems). Besides, it has been observed that data integrity was not assured in the quality control equipment and that - all things considered - there was a weak system in place for the investigation of deviations.
As a result of the inspection i.e. of the deficiencies discovered, the manufacturing authorisation of the company has been suspended.
Source: EMA's EudraGMDP database
Related GMP News
03.06.2026GMP Auditor Association Developments January through April 2026
20.05.2026CAPA and Root Cause Analysis - why FDA keeps calling them out
20.05.2026FDA Pilots One-Day Inspectional Assessments to Expand Oversight
06.05.2026FDA Warning Letter: CAPA not only needed for Deviations
28.04.2026FDA remains active in Europe - further Inspections despite MRAs


